2,244 press releases in English indexed under biotech & pharma.
Oncolytics announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
Research published in Frontiers in Bioengineering and Biotechnology demonstrated C‑1101 reduced inflammation and tissue breakdown while activating repair pathways — acting on the disease, not just the pain — in a nonclinical study Pain sensitivity also decreased in a second species,...
SANTA ANA, Calif., Sept. 10, 2026 -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the potential of troculeucel, the Company’s lead investigational program, for the treatment of neurodegenerative diseases at Biologics Manufacturing Korea 2026, taking place September 17-18, 2026, in Incheon, South Korea.
NEEDHAM, Mass., Sept. 10, 2026 -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Martine Zimmermann, PharmD, to the Company’s Board of Directors (Board) effective September 8, 2026.
– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
$2.7 million partnership advances workforce development to prepare the next generation of pharmaceutical manufacturing professionals in North Carolina. MONROE, N.C., Sept. 10, 2026 -- Glenmark Pharmaceuticals Inc. USA (Glenmark) joined South Piedmont Community College to...
DOYLESTOWN, Pa., Sept. 10, 2026 -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.
Chair of Translational Neuro-Oncology at the University of Manchester, previously a member of the Company's Scientific Advisory Board, elected at the 2026 Annual General Meeting Chair of Translational Neuro-Oncology at the University of Manchester, previously a member of the Company's Scientific Advisory Board, elected at the 2026 Annual General Meeting
DOWNLOAD MEDIA RELEASE Baar, Switzerland--(September 10, 2026) - medmix’ Drug Delivery (“Haselmeier”) announces its collaboration with Xeris Pharmaceuticals to support the development of Xeris’ XP-8121 product candidate, an investigational once-weekly subcutaneous levothyroxine therapy in development for the treatment of hypothyroidism. XP-8121 combines a proprietary high-concentration XeriSol® levothyroxine formulation with an adjustable pen injector...
New presentation offers convenient administration of GSK's shingles vaccine
VVMF has been granted a Licence to Manufacture Therapeutic Goods (GMP licence) from the Therapeutic Goods Administration (TGA) for their site in Sydney.
Basel, 10 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The filing acceptance is based on positive results from the Phase III METEOROID study, which showed that Enspryng provided consistent, clinically meaningful improvements for people living with MOGAD.1 This marks the second FDA Priority Review for Enspryng, following the one granted for thyroid eye disease (TED) in June 2026. The FDA is expected to make a decision on approval in MOGAD by 10 January 2027.